A 12-Week, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Kyowa Kirin Pharmaceutical Development
- 16 Sep 2020 Results of pooled analysis from four trials presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 16 Sep 2020 Results of pooled analysis from four pivotal trials presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 01 Feb 2012 Results published in Parkinsonism and Related Disorders.